Outlook Therapeutics, Inc.: Form 10-K for the period ended Sep 30, 2024
Filed with the SEC on Dec 27, 2024 and accepted by EDGAR at Dec 27, 2024, 21:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-10-01 to 2024-09-30 | $41.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-10-01 to 2024-09-30 | −$71.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-10-01 to 2024-09-30 | $3.2m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2023-10-01 to 2024-09-30 | $2.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-10-01 to 2024-09-30 | −$75.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-10-01 to 2024-09-30 | −$4.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-10-01 to 2024-09-30 | −$4.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-10-01 to 2024-09-30 | 18,548,813 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-10-01 to 2024-09-30 | −$68.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-09-30 | $14.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $27.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $28.8m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $42.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $101.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | −$73.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-016491. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.